Literature DB >> 20190000

Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

James F Meschia1, Peter Merrill, Elsayed Z Soliman, Virginia J Howard, Kevin M Barrett, Neil A Zakai, Dawn Kleindorfer, Monika Safford, George Howard.   

Abstract

BACKGROUND AND
PURPOSE: Warfarin reduces stroke risk by approximately 60% in patients with atrial fibrillation (AF). Differences in awareness and treatment of AF may contribute to racial and geographic disparities in stroke mortality. The objective was to examine predictors of awareness of the diagnosis of AF and treatment with warfarin.
METHODS: REasons for Geographic and Racial Differences in Stroke (REGARDS) is a national, population-based, longitudinal study of 30,239 blacks and whites > or = 45 years old with oversampling from blacks and the southeastern stroke belt states. Participants were enrolled January 2003 to October 2007. Data were collected using telephone interview, in-home evaluation, and self-administered questionnaires. The main variable of awareness of AF was defined by a positive answer to "Has a doctor or other health professional ever told you that you had atrial fibrillation?" and whether there was evidence of treatment on the basis of an in-home medications inventory.
RESULTS: From baseline electrocardiograms, 432 individuals (88 black and 344 white) had AF. Of these, 88% (360 of 409) had at least 1 additional CHADS2 stroke risk factor and 60% (258 of 432) were aware of their AF. The odds of blacks being aware of their AF were one third that of whites (OR=0.32; 95% CI: 0.20 to 0.52). Among those aware, the odds of blacks being treated with warfarin were only one fourth as great as whites (OR=0.28; 0.13 to 0.60).
CONCLUSION: Blacks were less likely than whites to be aware of having AF or to be treated with warfarin. Potential reasons for the racial disparity in warfarin treatment warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190000      PMCID: PMC2885129          DOI: 10.1161/STROKEAHA.109.573907

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

1.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

2.  Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  A S Go; E M Hylek; L H Borowsky; K A Phillips; J V Selby; D E Singer
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

3.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

4.  Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination.

Authors:  W J Jones; L S Williams; J F Meschia
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

5.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

6.  Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.

Authors:  Theodore Darkow; Ann M Vanderplas; Kim H Lew; Jennifer Kim; Ole Hauch
Journal:  Curr Med Res Opin       Date:  2005-10       Impact factor: 2.580

7.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care.

Authors:  David Williams; Kathleen Bennett; John Feely
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

9.  Reliability of the questionnaire for verifying stroke-free status.

Authors:  James F Meschia; Marc A Lojacono; Mary J Miller; Thomas G Brott; Elizabeth J Atkinson; Peter C O'Brien
Journal:  Cerebrovasc Dis       Date:  2003-12-29       Impact factor: 2.762

10.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Authors:  Alan S Go; Elaine M Hylek; Yuchiao Chang; Kathleen A Phillips; Lori E Henault; Angela M Capra; Nancy G Jensvold; Joe V Selby; Daniel E Singer
Journal:  JAMA       Date:  2003-11-26       Impact factor: 56.272

View more
  60 in total

1.  Identifying a high stroke risk subgroup in individuals with heart failure.

Authors:  Patrick M Pullicino; Leslie A McClure; Virginia J Howard; Virginia G Wadley; Monika M Safford; James F Meschia; Aaron Anderson; George Howard; Elsayed Z Soliman
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-12-03       Impact factor: 2.136

2.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

3.  Awareness, treatment and control of hypertension, diabetes and hyperlipidemia and area-level mortality regions in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Faisal M Shuaib; Raegan W Durant; Gaurav Parmar; Todd M Brown; David L Roth; Martha Hovater; Jewell H Halanych; James M Shikany; George Howard; Monika M Safford
Journal:  J Health Care Poor Underserved       Date:  2012-05

Review 4.  Ancel Keys Lecture: Adventures (and misadventures) in understanding (and reducing) disparities in stroke mortality.

Authors:  George Howard
Journal:  Stroke       Date:  2013-09-12       Impact factor: 7.914

Review 5.  Detection of atrial fibrillation and secondary stroke prevention using telemetry and ambulatory cardiac monitoring.

Authors:  Hooman Kamel; Wade S Smith
Journal:  Curr Atheroscler Rep       Date:  2011-08       Impact factor: 5.113

6.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

7.  Self-reported atrial fibrillation and risk of stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Elsayed Z Soliman; George Howard; James F Meschia; Mary Cushman; Paul Muntner; Patrick M Pullicino; Leslie A McClure; Suzanne Judd; Virginia J Howard
Journal:  Stroke       Date:  2011-08-04       Impact factor: 7.914

8.  Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States.

Authors:  Salina P Waddy; Allen J Solomon; Adan Z Becerra; Julia B Ward; Kevin E Chan; Chyng-Wen Fwu; Jenna M Norton; Paul W Eggers; Kevin C Abbott; Paul L Kimmel
Journal:  J Am Soc Nephrol       Date:  2020-02-20       Impact factor: 10.121

9.  National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries.

Authors:  Mukaila A Raji; Matthew Lowery; Yu-Li Lin; Yong-Fang Kuo; Jacques Baillargeon; James S Goodwin
Journal:  Ann Pharmacother       Date:  2013-01-16       Impact factor: 3.154

10.  Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Elsayed Z Soliman; Faye Lopez; Wesley T O'Neal; Lin Y Chen; Lindsay Bengtson; Zhu-Ming Zhang; Laura Loehr; Mary Cushman; Alvaro Alonso
Journal:  Circulation       Date:  2015-04-27       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.